Argenx, Zai Lab Shares Rise After Positive Trial Results for Vyvgart Hytrulo
17 Julho 2023 - 8:10AM
Dow Jones News
By Chris Wack
Argenx shares were up 25% to $474.87 in premarket trading after
the company said it and Zai Lab saw positive topline results from
their study evaluating Vyvgart Hytrulo, or efgartigimod alfa and
hyaluronidase-qvfc, in adults with chronic inflammatory
demyelinating polyneuropathy.
Zai Lab shares were up 10% to $30.49 in premarket trading.
The companies said the study met its primary endpoint,
demonstrating a significantly lower risk of relapse with Vyvgart
Hytrulo compared with placebo.
The study showed that the safety and tolerability profile was
consistent with confirmed safety profile of Vyvgart, and 91% of
eligible patients continued to the next phase of the open-label
extension study.
The most frequent treatment-related adverse event was injection
site reactions, which occurred in a lower percentage of patients
than previous Vyvgart Hytrulo trials. All injection site reactions
were mild to moderate and resolved over time.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 17, 2023 06:55 ET (10:55 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
argenx (NASDAQ:ARGX)
Gráfico Histórico do Ativo
De Mai 2024 até Mai 2024
argenx (NASDAQ:ARGX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024